Novel OA pain reliever lowered blood pressure.(Musculoskeletal Disorders): An article from: Family Practice News

This digital document is an article from Family Practice News, published by International Medical News Group on September 15, 2008.The length of the article is 434 words.The page length shown above is based on a typical 300-word page.The article is delivered in HTML format and is available immediately after purchase.You can view it with any web browser.Citation DetailsTitle: Novel OA pain reliever lowered blood pressure.(Musculoskeletal Disorders)Author: Bruce JancinPublication: Family Practice News (Magazine/Journal)Date: September 15, 2008Publisher: International Medical News GroupVolume: 38 Issue: 18 Page: 24(1)Distributed by Gale, a part of Cengage Learning

Published on: 2008-09-15 Released on: 2008-10-22 Format: HTML Binding: Digital 2 pages

Excerpt.В© Reprinted by permission.All rights reserved.PARIS -- Naproxcinod, an investigational pain reliever being developed for osteoarthritis, resulted in significantly lower blood pressure than did naproxen in a pivotal phase III clinical trial.Conventional NSAIDs such as naproxen, as well as selective cyclooxygenase (COX)-2 inhibitors, are known to affect blood pressure adversely and can counteract the benefits of antihypertensive agents.This hypertensive action is thought to be an important mechanism in the increased cardiovascular risk that has led to across-the board black box warnings for NSAIDs, Dr.Brigitte Duquesroix, director of clinical research at NicOx S.A., in Sophia Antipolis, France, noted at the annual European Congress of Rheumatology.

Hushovd surprises even himself with yellow jersey